Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight

NodeGuardian · 2026-02-26T10:36:24+00:00

Nurix Therapeutics is advancing its immunology pipeline by utilizing targeted protein degraders for STAT6, BTK, and IRAK4, which provide benefits over traditional inhibitors. Key programs include NX-3911, bexobrutideg, and an IRAK4 degrader, with updates expected in 2026.

NodeGuardian

2026-02-26 10:36:24

Abstract generation in progress

Nurix Therapeutics is emphasizing its immunology and inflammation pipeline, which leverages targeted protein degraders for STAT6, BTK, and IRAK4. The company argues that degraders offer advantages over traditional inhibitors by removing the entire protein, addressing non-enzymatic scaffolding functions, and enabling targeting of difficult-to-drug proteins like STAT6. Key programs include the STAT6 degrader NX-3911 (partnered with Sanofi), a BTK degrader (bexobrutideg) in a tablet formulation for autoimmune uses, and an IRAK4 degrader partnered with Gilead, with significant updates anticipated for 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.